Document is current
Any future updates will be listed below
-
Authors
Munkhbaatar, Enkhtsetseg https://orcid.org/0000-0002-2427-5952
Dietzen, Michelle
Agrawal, Deepti https://orcid.org/0000-0002-9541-1704
Anton, Martina https://orcid.org/0000-0001-5290-5213
Jesinghaus, Moritz
Boxberg, Melanie
Pfarr, Nicole https://orcid.org/0000-0002-5977-5375
Bidola, Pidassa
Uhrig, Sebastian
Höckendorf, Ulrike
Meinhardt, Anna-Lena
Wahida, Adam https://orcid.org/0000-0002-8856-8834
Heid, Irina
Braren, Rickmer https://orcid.org/0000-0001-6039-6957
Mishra, Ritu
Warth, Arne
Muley, Thomas https://orcid.org/0000-0002-8141-0604
Poh, Patrina S. P.
Wang, Xin https://orcid.org/0000-0002-3529-5780
Fröhling, Stefan https://orcid.org/0000-0001-7907-4595
Steiger, Katja https://orcid.org/0000-0002-7269-5433
Slotta-Huspenina, Julia
van Griensven, Martijn https://orcid.org/0000-0001-5104-9881
Pfeiffer, Franz
Lange, Sebastian https://orcid.org/0000-0003-0406-1401
Rad, Roland
Spella, Magda
Stathopoulos, Georgios T. https://orcid.org/0000-0002-9215-6461
Ruland, Jürgen https://orcid.org/0000-0002-8381-3597
Bassermann, Florian
Weichert, Wilko
Strasser, Andreas https://orcid.org/0000-0002-5020-4891
Branca, Caterina https://orcid.org/0000-0001-6231-2040
Heikenwalder, Mathias https://orcid.org/0000-0002-3135-2274
Swanton, Charles https://orcid.org/0000-0002-4299-3018
McGranahan, Nicholas https://orcid.org/0000-0001-9537-4045
Jost, Philipp J. https://orcid.org/0000-0003-2454-0362
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (111783)
- License Information
-
More Information
Article History
Received: 1 November 2019
Accepted: 20 August 2020
First Online: 10 September 2020
Competing interests
: S.F. has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from the following for-profit companies: Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca, and Pfizer. W.W. has attended Advisory Boards and served as speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Amgen and Astellas. W.W. receives research funding from Roche, MSD, BMS and Bruker. A.S. is an employee at The Walter and Eliza Hall Institute, which receives milestone payments and royalties from Genentech and AbbVie for the development of Venetoclax. A.S. has collaborations with Servier for the development of MCL-1 inhibitors for cancer therapy. N.P. has had a consulting or advisory role for Novartis. C.S. has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Pfizer, AstraZeneca, BMS, Roche Ventana, Boehringer Ingelheim, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, Illumina, Sarah Canon Research Institute, Genentech, Roche Ventana, GRAIL, Medicxi, and Dynamo Therapeutics. C.S. has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL. C.S. is co-founder and has stock options in Achilles Therapeutics. N.M. has stock options and has received consultancy fees from Achilles Therapeutics. P.J.J. has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, BMS, Boehringer, Novartis, Pfizer, Servier, and Celgene. All the other authors disclose no potential conflicts of interest.
